Navigating Novel Therapies in Steroid-Refractory cGVHD: Practical Strategies for Community-Based Oncology Pharmacists

Program Description

Chronic graft-versus-host disease (cGVHD) is a significant challenge in post-transplant care that can occur after an allogeneic hematopoietic stem cell transplant when donor immune cells recognize the recipient's tissues as foreign and attack them. Management of cGVHD often requires long-term treatment after transplant. When considering treatment for cGVHD, particularly in the third-line setting, the choice of therapy is multifactorial. Community-based oncology pharmacists play a crucial role in ensuring continuity of care, but face barriers like limited access to specialists, evolving treatment guidelines, and emerging targeted therapies. This webinar will explore therapy selection and sequencing in steroid-refractory cGVHD informed by clinical trial data and real-world insights. Key drug-specific characteristics, including dosing and dose adjustments, administration, monitoring requirements, and adverse event profiles, will also be detailed. Participants will recognize the importance of considering adverse effect profiles, patient-specific factors such as organ involvement, comorbidities, access to care, and financial toxicity, and the potential for combination therapy.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: September 16, 2025
Expiration date: September 16, 2026

Time to complete activity: 1.25 hours

Learner level: Foundational
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the mechanism of action of novel therapies for the treatment of steroid-refractory chronic graft-versus-host disease (cGVHD) and their relationship to disease pathophysiology
• Investigate the role of novel therapies in steroid-refractory cGVHD and supportive clinical evidence
• Apply a personalized approach to the management of steroid-refractory cGVHD by assessing key clinical and pharmacologic factors
• Employ pharmacist-directed strategies to optimize medication safety and adherence in cGVHD treatment

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.25 contact hours (0.125 CEU) under the ACPE universal activity number 0290-0000-25-303-H01-P. The activity is available for CE credit through September 16, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

LeAnne Kennedy, PharmD

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Amy L. Morris, PharmD; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms